First patient dosed in phase I/II trial of complement-targeting gene therapy for geographic atrophy

A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in geographic atrophy (GA) has begun dosing patients, marking an early step in expanding therapeutic strategies beyond currently approved complement inhibitors.

Complement Therapeutics GmbH announced that the first patient has received CTx001 in the phase I/II Opti-GAIN study (NCT07392255), which is assessing safety, tolerability, and preliminary efficacy in GA secondary to age-related macular degeneration (AMD).

GA remains a leading cause of irreversible vision loss in older adults, characterized by progressive degeneration of the retinal pigment epithelium and photoreceptors. Although recent approvals of complement inhibitors have introduced treatment options, their clinical benefit is modest and requires repeated intravitreal injections, underscoring ongoing unmet need.¹^,²

Trial design and early development strategy

Opti-GAIN is a multicenter, open-label, dose-escalation phase I/II study conducted in the United Kingdom. The trial consists of 2 parts: an initial dose-escalation phase across 3 cohorts followed by a dose-expansion phase. The investigational therapy, CTx001, is administered as a single subretinal injection.

The study’s primary objectives focus on safety and tolerability, consistent with early-phase gene therapy development, while exploratory endpoints include structural and functional measures of disease progression. Notably, the trial incorporates emerging imaging-based endpoints such as ellipsoid zone integrity and focal optical coherence tomography (OCT)-guided microperimetry, which may provide more localized functional assessment than traditional visual acuity metrics.

Complement Therapeutics is also conducting a parallel natural history study (NCT07144137) to better characterize disease progression and inform endpoint selection and patient stratification. While this integrated approach may strengthen future trial design, its impact on regulatory decision-making remains to be determined.

Mechanism of action and scientific rationale

CTx001 is an adeno-associated virus serotype 2 (AAV2)-based gene therapy designed to deliver a gene encoding mini–complement receptor 1 (mini-CR1), a truncated, secreted form of complement receptor 1. The expressed protein is intended to modulate both classical and alternative complement pathways locally within the retina.

Complement dysregulation has been strongly implicated in AMD pathogenesis through genetic and histopathologic studies, including associations with variants in complement factor genes such as CFH and C3.³⁻⁵ Current FDA-approved therapies—pegcetacoplan and avacincaptad pegol—target complement components C3 and C5, respectively, and have demonstrated reductions in GA lesion growth rates in phase III trials.¹² However, these agents require chronic administration and do not reverse established atrophy.

Gene therapy approaches such as CTx001 aim to provide sustained intraocular production of complement regulators after a single administration. Preclinical rationale suggests that the smaller size of mini-CR1 may facilitate diffusion across retinal layers, potentially enabling broader tissue coverage, including the choriocapillaris. However, clinical validation of this hypothesis is pending.

Clinical context and emerging treatment landscape

The introduction of complement inhibitors has shifted the treatment paradigm for GA, but several limitations persist. In phase III trials, pegcetacoplan reduced GA lesion growth by approximately 17% to 22% depending on dosing frequency, while avacincaptad pegol demonstrated a reduction of approximately 14% to 27%.¹ These effects, while statistically significant, translate into modest slowing of disease progression and require frequent intravitreal injections, raising questions about long-term adherence and real-world effectiveness.

Gene therapy strategies could address some of these limitations by reducing treatment burden and potentially enhancing durability. However, subretinal delivery involves a surgical procedure with associated risks, including retinal detachment and inflammation, which must be carefully evaluated in early-phase trials.

Interpretation and remaining questions

At this stage, the initiation of Opti-GAIN represents a developmental milestone rather than a clinically practice-changing event. No efficacy or safety data from human participants have yet been reported. As with other retinal gene therapies, key considerations will include durability of expression, control of intraocular inflammation, and consistency of surgical delivery.

Additionally, while complement inhibition is a validated therapeutic target in GA, it remains unclear whether broader modulation of multiple complement pathways, as proposed with mini-CR1, will translate into superior clinical outcomes.

Limitations and next steps

The primary limitation is the absence of clinical data beyond trial initiation. The small sample size and open-label design typical of phase I/II studies will limit interpretability of efficacy signals. Furthermore, the use of novel endpoints such as focal OCT-based microperimetry, while potentially informative, may present challenges in standardization and regulatory acceptance.

Future updates from Opti-GAIN will be needed to assess safety, preliminary efficacy, and feasibility of this gene therapy approach. Longer-term studies will ultimately be required to determine whether a one-time treatment can meaningfully alter the natural history of GA.

References

1. Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 3 trial (OAKS and DERBY). Ophthalmology. 2023;130(4):294-308. https://doi.org/10.1016/j.ophtha.2022.10.027

2. Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to AMD: results from a randomized phase 3 trial (GATHER2). Lancet. 2023;402(10415):1437-1447. https://doi.org/10.1016/S0140-6736(23)01883-7

3. Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48(2):134-143. https://doi.org/10.1038/ng.3448

4. Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular degeneration: a review of rare genetic variants and implications for personalized treatment. Mol Immunol. 2017;84:65-76. https://doi.org/10.1016/j.molimm.2016.11.016

5. ClinicalTrials.gov. A Study to Evaluate CTx001 in Patients With Geographic Atrophy (Opti-GAIN). https://clinicaltrials.gov/study/NCT07392255

6. ClinicalTrials.gov. Natural History Study in Geographic Atrophy (Pre-GAIN). https://clinicaltrials.gov/study/NCT07144137